A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Gidwani R, Khan ZM, Fenaux P, Beach CL, Pashos CL. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2012; 15(1):145-54.